tp53-aberrant mcl: challenges and treatment approaches
Published 1 year ago • 68 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
2:38
the boven trial: mrd-guided obinutuzumab, zanubrutinib and venetoclax regimen in tp53-mutated mcl
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
1:13
the challenges of treating patients with mpns who possess a tp53 mutation
-
1:40
new therapeutic approaches targeting xpo1-overexpression in tp53-mutated myeloid malignancies
-
1:53
challenges in treating patients with tp53-mutated aml and future outlooks
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:27
treatment options for patients with tp53-mutated aml
-
4:37
challenges in the diagnosis and treatment of vwd
-
2:32
how quickly does aml progress? #aml
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
1:08
novel strategies to target p53-mutant hematological malignancies
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
1:22
managing adverse events associated with btkis when treating patients with mcl
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
0:45
car-t resistance in tp53-mutated b-all: a loss of signalling
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:38
shared decision-making when selecting candidates for gene therapy in hemoglobinopathies
-
3:00
apr-246 in tp53 mutated mds and aml